Larimar Therapeutics (LRMR) Preferred Dividend Payments (2013 - 2014)
Larimar Therapeutics' (LRMR) quarterly Preferred Dividend Payments came in at $43000.0 in Q2 2014, down 20.37% on a YoY basis from $54000.0 in Q2 2013, and down 12.24% quarter-over-quarter from $49000.0 in Q1 2014.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Preferred Dividend Payments for 2 consecutive years, with $43000.0 the latest figure, recorded in Q2 2014.
- For the quarter ending Q2 2014, Preferred Dividend Payments fell 20.37% year-over-year to $43000.0; the trailing twelve-month figure through Dec 2014 stood at $92000.0 (changed N/A YoY), and the FY2014 full-year result was $92000.0, down 56.81% from the prior year.
- Preferred Dividend Payments eased to $43000.0 in Q2 2014 per LRMR's latest filing, from $49000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $54000.0 in Q2 2013 and bottomed at $43000.0 in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2014 | 43,000.00 |
| Mar 31, 2014 | 49,000.00 |
| Dec 31, 2013 | 53,000.00 |
| Sep 30, 2013 | 53,000.00 |
| Jun 30, 2013 | 54,000.00 |